To explore further whether stromal Cav-1 loss is an adverse prognostic biomarker in pancreatic cancer, the correlation between stromal Cav-1 expression and HER-2/neu gene amplification was analyzed. This evidence concerns the gene CAV1 and familial pancreatic carcinoma.